Multifactor Behavioral Treatment of Chronic Sleep-Onset Insomnia Using Stimulus Control and the Relaxation Response: A Preliminary Study

Authors
Gregg D. Jacobs, Paul A. Rosenberg, Richard Friedman, Jean Matheson, Guerry M. Peavy, Alice D. Domar, Herbert Benson
Publication
Behavior Modification
Volume 17, Issue 4
Abstract

Sleep latency changes following behavioral interventions for sleep-onset insomnia are only moderate because the majority of insomniacs do not achieve good sleeper status at posttreatment. This study evaluated the efficacy of a multifactor behavioral intervention consisting of stimulus control and relaxation-response training (n = 10) compared to stimulus control alone (n = 10) for sleep-onset insomnia. Only the multifactor subjects’ mean posttest sleep latency fell within the good sleeper range. They also exhibited a 77% improvement on mean sleep-onset latency compared to the stimulus control group (63%). Thus a multifactor intervention may be more effective than stimulus control alone for treatment of sleep-onset insomnia.

Related Listings
Reduced Pupillary Sensitivity to Topical Phenyl...
Authors
John W. Lehmann, Irene L. Goodale, Herbert Benson
Journal
Journal of Human Stress
·
Human pupillary dilatation after topical instillation of phenylephrine was assessed in a prospective, randomized, controlled experiment to measure alterations in α-end-organ responsivity after regular elicitation of the relaxation response. Baseline pupillometric measurements were taken in both experimental and control subjects. The experimental subjects then practiced daily a technique that elicited the relaxation response while the control subjects sat quietly for comparable periods […]
Neuroscience Reveals the Secrets of Meditation’...
Authors
Richard J. Davidson, Matthieu Ricard, Antoine Lutz
Journal
Scientific American
·
A very readable introduction to the scientific findings in neurology about primarily Buddhist forms of meditation.
Kundalini Yoga Meditation Versus the Relaxation...
Authors
David Shannahoff-Khalsa, Rodrigo Yacubian Fernandes, Carlos A. de B. Pereira, John S. March, James F. Leckman, Shahrokh Golshan, Mario S.R. Vieira, Guilherme V. Polanczyk, Euripedes C. Miguel, Roseli G. Shavitt
Journal
Frontiers in Psychiatry
Background: Obsessive-compulsive disorder (OCD) is often a life-long disorder with high psychosocial impairment. Serotonin reuptake inhibitors (SRIs) are the only FDA approved drugs, and approximately 50% of patients are non-responders when using a criterion of 25% to 35% improvement with the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). About 30% are non-responders to combined first-line therapies (SRIs and exposure and response prevention). Previous research (one open, one randomi […]